Taysha Gene Therapy Update

In their press release dated 28th March 2023 Taysha shared important updates to their gene therapy programme for Rett syndrome. Read the full press release here.

Taysha has initiated screening of the first potential participant in the Phase 1/2 REVEAL adult study in Canada and is planning to dose the first participant with the investigational gene therapy (TSHA-102) in the first half of 2023.

Taysha has submitted a protocol amendment to potentially allow for younger participants in the ongoing REVEAL adult study in Canada. The proposed amendment is to reduce the age criteria from 18 years and older to 15 years and older.

Taysha remains on track to submit a Clinical Trial Application (CTA) to the United Kingdom MHRA for TSHA-102 in pediatric females living with Rett syndrome in mid-2023 and an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) in the second half of 2023.

Taysha Gene Therapy Update
Scroll to top